The European Medicines Agency publishes a report suggesting a "possible link" between usage of the Johnson & Johnson COVID-19 vaccine candidate and rare blood clots. The agency maintains, however, that the overall benefits of the shot "outweigh the risks of side effects."
The European Medicines Agency publishes a report suggesting a "possible link" between usage of the Johnson & Johnson COVID-19 vaccine candidate and rare blood clots. The agency maintains, however, that the overall benefits of the vaccine outweigh the risks of side effects.
